Skip to main content
EQ
NASDAQ Life Sciences

President & CSO Stephen Connelly files to sell $632K in shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.16
Mkt Cap
$200.428M
52W Low
$0.27
52W High
$3.45
52W Position info
1070% above low
Off High info
8.4% below high
Rel. Volume info
2.8× avg
Market data snapshot near publication time

EQ has more than doubled off its 52-week low of $0.27 on elevated volume (2.8× avg).

Summary

Equillium's President and CSO, Stephen Connelly, intends to sell over $632,000 worth of common stock, marking a notable insider disposition.


Key Events · Ownership and Investor Activity · EQ

  • Officer Files Intent to Sell Shares

    Stephen Connelly, President and CSO, filed a Form 144 to sell 200,000 shares of common stock.

  • Significant Value of Proposed Sale

    The proposed sale is valued at approximately $632,760, representing 0.32% of the company's current market capitalization.

  • Adds to Insider Distribution Trend

    This filing contributes to a recent pattern of insider sales, with over $1.45 million in net sales by insiders in the last 90 days.

  • Long-Held Founders Shares

    The shares intended for sale were acquired as founders shares in May 2017, indicating a disposition of long-term holdings.


Analysis · EQ · Life Sciences

Stephen Connelly, President and CSO, has filed a Form 144 indicating his intent to sell 200,000 shares, valued at approximately $632,760. This represents a significant disposition by a key executive, following recent capital raises and shareholder approval for a reverse stock split. The sale adds to a recent trend of insider distribution.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EQ was trading at $3.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $200.4M. The 52-week trading range was $0.27 to $3.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EQ - Latest Insights

EQ
Nov 12, 2026, 4:20 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.34
Real-time Price: $1.12 info
Change: -$0.220 (-16%) info
Market Cap: $92.204M info
EQ
Oct 26, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.29
Real-time Price: $1.12 info
Change: -$0.170 (-13%) info
Market Cap: $92.204M info
EQ
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $1.12 info
Change: -$0.0003 (-0.03%) info
Market Cap: $92.204M info
EQ
Oct 05, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $1.12 info
Change: -$0.300 (-21%) info
Market Cap: $92.204M info
EQ
Oct 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.12 info
Change: -$0.390 (-26%) info
Market Cap: $92.204M info